MetaCap

IRulya Therapeutics Inc. Company Profile

NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.88-0.06 (-0.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRulya Therapeutics at a glance

IRulya Therapeutics Inc. (NASDAQ: IRLA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in New Haven, CT. IRulya Therapeutics is led by Dr. Brigette Roberts M.D. and employs about 38 people. The company's shares have traded publicly since 2019.

At a market capitalization of $433.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001662774, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does IRulya Therapeutics do?

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in New Haven, Connecticut.

Business description based on the company's public filings.

Company information

Legal name
IRulya Therapeutics Inc.
Ticker
NASDAQ: IRLA
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Brigette Roberts M.D.
Employees
38
Headquarters
101 College Street, New Haven, CT, United States
Phone
415 910 5717
Website
irulya.com
IPO year
2019
Market cap
$433.01M
SEC CIK
0001662774
Latest annual report
10-K · Apr 10, 2026

Companies similar to IRulya Therapeutics

IRLA peer companies
CompanyPrice% ChgMarket capCompare
PROKProKidney Corp. Class A1.04-1.89%$415.21Mvs IRLA
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs IRLA
TVGNTevogen Inc.5.90-6.35%$405.20Mvs IRLA
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs IRLA
CADLCandel Therapeutics Inc.5.04-1.75%$395.37Mvs IRLA
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs IRLA
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs IRLA
DNAGinkgo Bioworks Holdings Inc. Class A7.46-9.02%$483.54Mvs IRLA

Related